Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy

Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic

“…Treatment with immunomodulatory therapies has not been associated with increased prevalence or severity of COVID-19 infection. 1,2 As guidelines for biologic agents continue to evolve during the pandemic, inclusion of new data is essential to optimize management for a wide range of inflammatory disorders. 3 Since the majority of our patients with hidradenitis suppurativa (HS) receive anti-TNF-α therapy, we sought to examine the occurrence and outcomes of COVID-19 in this cohort.…”

COVID-19 and Dermatology in Iran

“…In the current studies, patients on the systemic immunomodulatory therapy had similar infection rates compared to the general population. 5 , 6 , 7 , 8 The mortality rate adjusted by age and sex did not increase in the patients who had received the immunosuppressive therapies. 9 …”

New Onset Granulomatosis with Polyangiitis Associated with COVID-19

“…In the setting of coronavirus, there is a concern that immunosuppressive therapies could increase the likelihood of adverse events including hospitalization and mortality [ 10 , 11 ]. However, other studies suggest that the increased risk of COVID-19-related adverse events (such as admission to an intensive care unit or requiring mechanical ventilation) is minimal, and outcomes are improved when patients are on immune-modifying medications [ 10 , 12 ]. Furthermore, patients given dexamethasone, a well-known immunomodulatory therapy, had significantly lower mortality and length of hospital stay [ 11 ].…”